Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28300287 | 0.85 | LMNA (0.62) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL20446704 | 0.85 | LMNA (0.62) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL8006539 | 0.80 | MEN1 (0.55) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL4470862 | 0.79 | NFE2L2 (0.59) | KDM4ECYP1A2MEN1KMT2ALMNA | |
| 1,2-Diethoxybenzene SCHEMBL28400278 | 0.79 | L3MBTL1 (0.66) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL31401930 | 0.77 | ALDH1A1 (0.73) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL535646 | 0.77 | ALDH1A1 (0.73) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL2488791 | 0.77 | ALDH1A1 (0.54) | KDM4ECYP1A2CYP2C9MEN1KMT2A | |
| SCHEMBL1536281 | 0.76 | PTGER1 (0.66) | KDM4EKMT2ALMNAL3MBTL1GLA | |
| SCHEMBL4739417 | 0.76 | KDM4E (0.57) | KDM4ECYP1A2CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | ARES TRADING SA (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9932354-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-2855488-B1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | ARES TRADING SA (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20150175628-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | APP, BACE1, PSEN1 | KDM4E 4491/4885CYP1A2 964/4885CYP2C9 2557/4885 |
| US-20150175628-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | APP, BACE1, PSEN1 | KDM4E 4491/4885CYP1A2 964/4885CYP2C9 2557/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | KDM4E 4491/4885CYP1A2 964/4885CYP2C9 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.